Trimeris also has a second-generation entry inhibitor
in early clinical trials.
On the whole, entry inhibitors
appear to be the next new weapon against HIV.
In the area of virology, Progenics is developing the HIV entry inhibitor
PRO 140, a humanized monoclonal antibody targeting the entry co-receptor CCR5, which is currently in phase 2 clinical testing.
Viral entry inhibitors
represent a novel and interesting new class of antiviral agents," said John McHutchison, MD, Professor of Medicine at Duke University and Chairman of iTherX Scientific and Clinical Advisory Board.
In November, Progenics also announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, a novel HCV entry inhibitor
for clinical development as a treatment of hepatitis C virus (HCV) infection.
5 (intermediate 0 (low penetration) penetration) Nucleoside or nucleotide reverse transcriptase inhibitors Retrovir (zidovudine) Emtriva Videx (didanosine) (emtricitabine) Ziagen (abacavir) Epivir (lamivudine) Viread (tenofovir) Zerit (stavudine) Nonnucleoside reverse transcriptase inhibitors Viramune (nevirapine) Sustiva (efavirenz) Intelence (etravirine) * Protease inhibitors Crixivan (indinavir) Reyataz (atazanavir) Aptivus (tipranavir) + (+ RTV) RTV Kaletra (lopinavir + Reyataz + RTV Invirase (saquinavir) RTV) + RTV Agenerase[dagger] Prezista (darunavir) + Norvir (ritonavir) (amprenavir) + RTV RTV Viracept (nelfinavir) Entry inhibitors
Selzentry Fuzeon (enfuvirtide) (maraviroc) * Integrase inhibitors Isentress (raltegravir) * RTV = ritonavir (Norvir).
Mitsuya also made a direct contribution to advancing research and development into entry inhibitors
and the clinical implementation of
All the other products mentioned are called HIV entry inhibitors
and block HIV infection.
SAN FRANCISCO -- Efforts to develop entry inhibitors
, which constitute the first new class of anti-HIV drugs in years, have hit snags that could delay the entry of these novel agents into the pharmaceutical marketplace.
Three CCR5 entry inhibitors
have recently been in large clinical trials: aplaviroc from GlaxoSmithKline, maraviroc from Pfizer, and vicriviroc from Schering Plough.
But new entry inhibitors
, which will be taken orally, should be available very soon.
In order to efficiently block intracellular fusion events, the next generation of HIV entry inhibitors
must be able to permeate the cell membrane," he added.